-
Signature
-
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
-
Issuer symbol
-
RNA
-
Transactions as of
-
05 Sep 2025
-
Net transactions value
-
-$1,294,040
-
Form type
-
4
-
Filing time
-
09 Sep 2025, 17:53:21 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| WILSON TROY EDWARD |
Director |
C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN RD., SAN DIEGO |
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact |
09 Sep 2025 |
0001589597 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RNA |
Common Stock |
Options Exercise |
$180,960 |
+14,500 |
+21% |
$12.48 |
83,925 |
05 Sep 2025 |
Direct |
F1 |
| transaction |
RNA |
Common Stock |
Sale |
$725,000 |
-14,500 |
-17% |
$50.00 |
69,425 |
05 Sep 2025 |
Direct |
F1 |
| transaction |
RNA |
Common Stock |
Sale |
$750,000 |
-15,000 |
-22% |
$50.00 |
54,425 |
05 Sep 2025 |
Direct |
F1 |
| holding |
RNA |
Common Stock |
|
|
|
|
|
13,711 |
05 Sep 2025 |
By family trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RNA |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-14,500 |
-100% |
$0.000000 |
0 |
05 Sep 2025 |
Common Stock |
14,500 |
$12.48 |
Direct |
F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: